FBB Biomed is delighted to announce the filing of a groundbreaking patent application.?This patent covers diagnostic claims for 11 neurologic diseases, including Long Covid, Parkinson’s, Multiple Sclerosis, and Alzheimer’s, as well as 8 cancers and 2 autoimmune diseases. These results are only possible because of the investors who support our revolution of diagnostics - via a minimally invasive blood test powered by AI and cutting-edge genomics. We want to thank our existing investor?Loyal VC for their multi-year support and welcome the support of any who want to take part in creating the?future of healthcare. Contact us at?[email protected].
关于我们
RNA diagnostics startup that offers the first alternative to the spinal tap
- 网站
-
https://www.fbbbio.com
FBB Biomed的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Coralville，Iowa
- 类型
- 私人持股
地点
-
主要
获取路线
US，Iowa，Coralville，52241
FBB Biomed员工
-
Howard Urnovitz
Founder - The Golden Age of Virology
-
Michael S. Chimenti, Ph.D.
Director of Bioinformatics, Iowa Institute of Human Genetics
-
Lindsey Kaschmitter
Research Analyst at FBB Biomed
-
Heinz Dr. H?nel
Vorstand bei Oxy5, benfovir, Advisor bei FBB Bio, Aprofol, Mitodicure und Taurus Advisory
动态
-
FBB Biomed转发了
Bridging the Gap in Mental Health Drug Development with Precision Biomarkers? Mental health drug development remains one of the biggest challenges in the pharmaceutical industry due to the lack of clear biological targets. Unlike oncology or autoimmune diseases, where scientists can biopsy tumors or measure immune markers, psychiatric disorders rely heavily on subjective patient reports rather than objective biomarkers. This fundamental gap has led to high failure rates, unpredictable trial outcomes, and reduced investment from major drugmakers. That’s why we developed our RUO test—to introduce precision medicine into neuropsychiatric trials. Our patent application has already demonstrated that we can accurately detect blood biomarkers associated with depression and schizophrenia, providing an objective foundation for patient stratification. By incorporating biomarkers into clinical trials, we help pharmaceutical companies de-risk trials, improve patient selection, and reduce costs, ultimately increasing the likelihood of regulatory success.? For decades, mental health treatments have remained largely unchanged, with refinements of drugs discovered serendipitously over 70 years ago. Many psychiatric trials still fail because they lack the ability to identify true responders—leading to wasted resources and late-stage failures. With rising patient demand and few innovative treatments reaching the market, the need for a data-driven approach to mental health drug development has never been greater. Our RUO test empowers companies to enhance inclusion/exclusion criteria, optimize trial efficiency, and bring targeted therapies to market faster. The future of neuropsychiatric drug development will rely on precision biomarkers—and we are ready to help pharmaceutical partners lead the way. Partner with Us: https://lnkd.in/eig9xbWn We’re collaborating with researchers and drug developers to advance biomarker-driven neuropsychiatric research. Join us in reshaping mental health drug development with precision diagnostics.
-
Contact us to learn more: [email protected]
Our research use only test aims to clarify the complexities of chronic illnesses by analyzing data to reclassify these diseases based on activated ancestral gene patterns. This approach seeks to uncover the genetic foundations of chronic conditions, providing clearer definitions and insights into their development. Recent advancements in artificial intelligence (AI) have significantly enhanced our understanding of gene activity across various chronic diseases. This capability allows researchers to identify specific gene expression patterns associated with various diseases, offering potential insights into their underlying mechanisms. Notably, these AI-driven analyses can be conducted using data obtained from simple blood tests, providing a minimally invasive method to study gene activation. This approach holds promise for developing targeted prevention strategies and therapeutic interventions, ultimately aiming to reduce or eliminate the burden of chronic illnesses. Ultimately, our objective is to redefine chronic conditions by establishing disease classification patterns based on ancestral gene expression, thereby eliminating uncertainty in diagnosis and treatment.
-
Contact us to learn more! [email protected] https://www.fbbbio.com
Dementia affects millions worldwide, with its prevalence steadily climbing. What often goes unrecognized, however, is that by the time symptoms like memory loss, confusion, or personality changes appear, the disease has already been progressing for years, undetected. This long, silent phase is when the greatest opportunities for intervention lie—but traditional diagnostic methods miss these early warning signs. Research has illuminated many potential risk factors, but much remains unknown about how to detect and treat dementia before irreversible damage occurs.? Our Research Use Only (RUO) test is designed to identify dementia in its earliest stages, long before symptoms manifest. Detecting these early indicators of the disease when interventions are still possible can make a profound difference. As we often say, "It’s easier to put out a match than a forest fire." By catching dementia early, we can shift the focus from managing decline to enabling prevention and cure—offering hope to millions and transforming the trajectory of this devastating condition.? https://lnkd.in/gB2dEd9p
-
FBB Biomed转发了
Transforming Alzheimer’s Diagnosis: A Biomarker-Driven Approach The redefinition of Alzheimer’s disease (AD) as a continuum of biological changes detectable before cognitive symptoms is transforming medicine. Advances like blood-based biomarkers are reshaping how we identify and understand this condition. Our biomarker test plays a crucial role in this shift, providing accurate insights into early-stage AD biology. Identifying individuals at risk or in the early phases supports a move from symptom-driven diagnoses to biology-based detection, enabling timely research and empowering individuals to prepare for the future while advancing life-changing therapeutics. Designed to provide clinicians with precise, actionable insights alongside other lab results, our test aids informed medical decisions. Clinicians interpret results within the context of a patient’s health and communicate findings to patients, ensuring compliance with Research Use Only (RUO) guidelines for physician-led evaluations. More news on the availability of the test is coming soon!
-
FBB Biomed转发了
Join us on Tuesday 3 December to catch our webinar, "The role of endogenous ancestral nucleotide sequences in health and disease", presented by Dr. Howard Urnovitz, CEO of FBB Biomed, and hosted by SelectScience?. ? #Genomics #MolecularDiagnostics
Could viruses in our DNA hold the key to neurodegenerative diseases like Parkinson’s and Alzheimer’s? Join Dr. Howard Urnovitz, CEO of FBB Biomed, to explore how RNA sequencing and AI are uncovering the role of endogenous ancestral nucleotide sequences (EANS) in health and disease. Register now: https://lnkd.in/e5A7UA8h #Neurodegeneration #AIinScience #Parkinsons #Alzheimers #RNASequencing #Genomics LGC Biosearch Technologies
-
-
It’s a great honor to be part of Iowa’s vibrant entrepreneurial ecosystem. We’re excited to contribute to expanding Iowa’s leadership beyond agriculture, embracing high-tech innovation and fostering growth in cutting-edge industries like ours.
?? Every month, I write a newsletter for Iowa entrepreneurs to get more connected to the strong networks of support in the Midwest (and beyond). Catch the Twenty-fourth edition of Startup Iowa Hot List: https://lnkd.in/g5e3rRuj
-
-
A Breakthrough Approach in Parkinson’s Diagnostics Parkinson’s Disease is one of the most urgent challenges in neurology today. As cases rise, we must ask: Are we equipped with the right tools to make a real difference? Emerging evidence suggests an even larger wave of Parkinson’s cases than previously expected, compounded by the aftermath of the COVID-19 epidemic. With complications now among the top 15 leading causes of death in the U.S., it’s clear that yesterday’s diagnostic methods won’t meet tomorrow’s challenges. At FBB Biomed, we’re working tirelessly to change that. Our groundbreaking blood test for early-stage Parkinsonian diseases offers a minimally invasive alternative to traditional spinal taps and brain scans, allowing healthcare professionals to detect neurological conditions earlier than ever. That’s why I’m excited to personally invite you to The Parkinson’s Solutions Summit 2.0, a virtual event designed for healthcare professionals dedicated to advancing Parkinson’s care. >> Unlock the future of Parkinson’s diagnostics<< This summit isn’t just another event—it’s a chance to learn from top innovators in Parkinson’s research and care, including experts like Dr. Kenneth Sharlin and Dr. Barbara Pickut. Here’s what you can expect: ???Breakthrough research in diagnostics?? Get exclusive insights into the latest advancements in Parkinson’s care, including our cutting-edge blood test technology. Starting next January, this technology will be available as a Research Use Only test, offering healthcare professionals valuable information with the intent to improve patient outcomes. ???Patient-first care strategies?? Learn how to develop personalized care plans that go beyond symptom management and address the root causes of Parkinson’s disease. ???Collaborative community?? Join a network of passionate healthcare professionals eager to exchange knowledge, discuss cases, and build a stronger future for Parkinson’s treatment. ???Convenient access? Attend the summit from your home or office—on your laptop, tablet, or phone. It’s designed to fit seamlessly into your busy schedule. The Parkinson’s Solutions Summit 2.0 is about more than just sharing information—it’s about shaping the future of Parkinson’s care together. With breakthrough technologies like those from FBB Biomed, we can revolutionize how we diagnose, treat, and ultimately transform the trajectory of Parkinson’s disease. >> Bring real, innovative solutions to Parkinson’s patients << Don’t miss this opportunity to learn, connect, and lead the way in Parkinson’s care. Register now to be part of this groundbreaking event! See you at the summit,? FBB Biomed P.S. Don’t miss out—join other forward-thinking professionals in transforming Parkinson’s diagnostics and care. Register for?free?and help shape the future of healthcare: https://lnkd.in/ePhhTuBN
-
-
Exciting News!?We are thrilled to announce that FBB Biomed has just received IRB approval to validate our minimum viable product in a clinical study focused on validating biomarkers in patients suffering from long COVID-19. In addition to long COVID, this study will include individuals with other neurological and respiratory diseases, expanding the scope of our research. With IRB approval, we’re now able to conduct a rigorous clinical study with the following objectives: Primary Objective: The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID. Secondary Objective: The secondary objective of this study is to determine if it is possible to develop an algorithm that can subclassify specific blood RNA biomarkers in long COVID patients into various symptom-related subcategories to provide clinically relevant treatment options. This is a significant step forward for FBB Biomed, and we’re excited to see where this journey leads. Stay tuned for more updates! In my next post, I’ll share where you can follow the study on clinicaltrials.gov. For those interested in learning more or exploring how to get involved in the next phase of our growth, feel free to reach out at [email protected]. #dementia #alzheimers #venturecapital #angelinvestor #cancer #hivaids??#bioOS?#biotechnology?#diagnostics #innovation?#technology?#management?#startups?#liquidbiopsy #neurodegenerativediseases?#multiplesclerosis?#parkinsonsdisease?#alzheimersdisease?#longhaulers?#longcovid?#humangenome?#onetestonelife #longevity?#artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine #ClinicalResearch #COVID19 #Parkinsons #climatechange?
-
-
FBB Biomed转发了
Prof. Ehrlich, we found the targets for your magic bullets! We updated our video from three years ago and posted it on our new website, https://www.fbbbio.com. #venturecapital #angelinvestor #cancer #hivaids #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention OK
FBB Biomed highlight - ADLM
https://www.youtube.com/